Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Sintilimab + GemCis in First-line Biliary Tract Cancer
NCT04300959Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib and sintilimab in biliary tract cancer (BTC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 12 months Overall Survival Rate. Status: unknown.
02
Drugs
anlotinibsintilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04300959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300959.